Prograf 5 mg/ml concentrate for solution for infusion

DRUG3 trials

Sponsors

Eledon Pharmaceuticals Inc., Centre Hospitalier Universitaire De Nantes

Conditions

Prophylaxis of Renal Allograft Rejectionchronic renal failure requiring kidney transplantation

Phase 1

Eight-Treg study: a phase I dose escalation trial of adoptive immunotherapy with autologous ex vivo expanded regulatory CD8+ T cells in living donor kidney transplant recipients

RecruitingCTIS2024-513771-40-01

Centre Hospitalier Universitaire De Nanteschronic renal failure requiring kidney transplantation

Start: 2025-03-03Target: 9Updated: 2024-12-20

Phase 2

BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Active, not recruitingCTIS2023-503336-41-00

Eledon Pharmaceuticals Inc.Prophylaxis of Renal Allograft Rejection

Start: 2023-11-29Target: 101Updated: 2025-07-22

BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Active, not recruitingCTIS2023-503337-21-00

Eledon Pharmaceuticals Inc.Prophylaxis of Renal Allograft Rejection

Start: 2025-02-28Target: 30Updated: 2025-08-12